Stage II T3/T4
Colorectal cancer, MMR-proficient.
DiaSurv® sorts stage II colorectal cancer by risk of recurrence.
It reads the H&E slide to separate higher-risk from lower-risk patients in stage II T3/T4, MMR-proficient disease, so follow-up and treatment match the real risk.
RESEARCH USE ONLYNot for use in diagnostic procedures
RESEARCH FOCUS
Stage II,
MMR-proficient.
The programme focuses on a population where the recurrence-risk question is open.
Recurrence risk
Explore which patients face a higher risk of recurrence.
Treatment intensity and follow-up
Help tailor treatment intensity and follow-up to the patient.
EVIDENCE
Evidence in colorectal cancer.
Validation of DiaSurv an AI-Based Algorithm for Stage II Colon Risk Stratification
Adjuvant chemotherapy decisions in stage II colon cancer (IIA T3N0; IIB T4aN0; IIC T4bN0) remain challenging, as conventional risk factors poorly predict…
Read more ↗︎Validation of DiaSurv, an AI-based algorithm for stage II colon cancer risk stratification
Adjuvant chemotherapy decisions in stage II colon cancer (IIA T3N0; IIB T4aN0; IIC T4bN0) remain challenging, as conventional risk factors poorly predict…
Read more ↗︎Multicentric evaluation of an artificial intelligence model to stratify stage II colon cancer patients from whole slide images
Stage II colon cancer (IIA T3N0; IIB T4aN0; IIC T4bN0) represents nearly 25% of all colon cancers and includes a wide range of outcomes (5-year overall…
Read more ↗︎RESEARCH COLLABORATION